Drug name - Briviact

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6911461 UCB INC 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Feb, 2026

(3 years from now)

CN1740151A UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Sep, 2007

(15 years ago)

CN1740150A UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Oct, 2007

(14 years ago)

CN1303066C UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Jul, 2010

(12 years ago)

CN1680314A UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Jul, 2010

(12 years ago)

CN1404470A UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Apr, 2015

(7 years ago)

CN1179944C UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Apr, 2015

(7 years ago)

CN1404469A UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Feb, 2021

(1 year, 7 months ago)

CN1208319C UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Feb, 2021

(1 year, 7 months ago)

IN200500340P3 UCB INC Compound Of General Formula (A)
Feb, 2021

(1 year, 7 months ago)

IN200201000P3 UCB INC A 2-Oxo-1-Pyrrolidine Compound Or Pharmaceutical Salts Thereof
Feb, 2021

(1 year, 7 months ago)

IN196025B UCB INC [2-Oxo-1-Pyrrolidine Derivatives] Process For Preparing
Feb, 2021

(1 year, 7 months ago)

IN200075B UCB INC A 2- Oxo-1-Pyrrolidine Compound Or Pharmaceutical Salts
Feb, 2021

(1 year, 7 months ago)

IN234848B UCB INC Compound Of General Formula (A)
Feb, 2021

(1 year, 7 months ago)

EP1447399B9 UCB INC 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses
Feb, 2021

(1 year, 7 months ago)

EP1447399B1 UCB INC 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses
Feb, 2021

(1 year, 7 months ago)

EP1447399A1 UCB INC 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses
Feb, 2021

(1 year, 7 months ago)

EP1477478A2 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses.
Feb, 2021

(1 year, 7 months ago)

EP1477478A3 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses.
Feb, 2021

(1 year, 7 months ago)

EP1263727A1 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses
Feb, 2021

(1 year, 7 months ago)

EP1265862A2 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Processes For Preparing Them And Their Uses
Feb, 2021

(1 year, 7 months ago)

EP1477478B1 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses.
Feb, 2021

(1 year, 7 months ago)

EP1265862B1 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Processes For Preparing Them And Their Uses
Feb, 2021

(1 year, 7 months ago)

EP1263727B1 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses
Feb, 2021

(1 year, 7 months ago)

EP1452524B1 UCB INC 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses
Feb, 2021

(1 year, 7 months ago)

EP1452524A1 UCB INC 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses
Feb, 2021

(1 year, 7 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653 UCB INC Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives Apr, 2030

(7 years from now)

Drugs and Companies using BRIVARACETAM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/5ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.